TapImmune to Present at World Vaccine & Immunotherapy Congress West Coast

JACKSONVILLE, Florida, November 17, 2017 / TapImmune Inc. (NASDAQ: TPIV), a leading clinical-stage immuno-oncology company with ongoing clinical trials in ovarian and breast cancer, today announced its Chairman and Strategic Advisor Glynn Wilson, Ph.D., and Senior Director of Molecular Biology & Virology Robert Florkiewicz, Ph.D., will give an oral presentation titled, “Increasing the potency of DNA-based immunotherapies using PolyStart™ peptide expression system,” at the World Vaccine & Immunotherapy Congress West Coast, held Thursday, November 30 – December 1, 2017, at the Loews Coronado Bay Resort in San Diego, CA.

The presentation will highlight data on the Company’s proprietary DNA vaccine technology, PolyStart™, and its use in driving DNA vaccine antigen expression and presentation to enable increased visibility of tumor cells to the immune system and more effectively target the cytotoxic activity of CD8+ killer T-cells.

Dr. Wilson and Dr. Florkiewicz will be available for one-on-one meetings at the conference.

TapImmune Event Details:

Title: Increasing the potency of DNA-based immunotherapies using PolyStart™ peptide expression system

Date: Thursday, November 30, 2017

Time: 3:45 p.m. (Pacific Time)

Location: Loews Coronado Bay Resort, San Diego, CA[/vc_column_text][vc_empty_space height=”8px”][vc_column_text][pr-disclaimer]